Current filters:

VaccinesRare diseases

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra


Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

FDA approves Incytes’ Jakafi, first drug to treat MF; advisory panel backs Pfizer’s Prevnar 13 for adults


USA-based Incyte (Nasdaq: INCY) saw its shares rise 10% to$13.90 on the news that the Food and Drug Administration…

BiotechnologyIncyteJakafiNorth AmericaNovartisPfizerPharmaceuticalPrevnarRare diseasesRegulationruxolitinibVaccines

Biovest sees mantle cell lymphoma as next target indication for personalized cancer vaccine


Florida, USA-based Biovest International yesterday announced at the Active Immunotherapeutics Forum in…

BiovaxIDBiovest InternationalOncologyPharmaceuticalRare diseasesResearchVaccines

Back to top